Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 3/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288356 | 1.00 | S1PR2 (0.57) | S1PR2S1PR1ALDH1A1GPR84SLC1A2 | |
| SCHEMBL5496400 | 1.00 | S1PR2 (0.57) | S1PR2S1PR1ALDH1A1GPR84SLC1A2 | |
| SCHEMBL287826 | 0.93 | S1PR2 (0.60) | S1PR2S1PR1ALDH1A1GPR84SLC1A2 | |
| SCHEMBL626959 | 0.93 | S1PR2 (0.60) | S1PR2S1PR1ALDH1A1GPR84SLC1A2 | |
| SCHEMBL4411200 | 0.93 | S1PR2 (0.60) | S1PR2S1PR1ALDH1A1GPR84SLC1A2 | |
| SCHEMBL10804885 | 0.91 | S1PR2 (0.63) | S1PR2S1PR1ALDH1A1GPR84S1PR3 | |
| SCHEMBL22660994 | 0.91 | S1PR2 (0.63) | S1PR2S1PR1ALDH1A1GPR84S1PR3 | |
| SCHEMBL5419098 | 0.91 | S1PR2 (0.63) | S1PR2S1PR1ALDH1A1GPR84S1PR3 | |
| SCHEMBL11437074 | 0.91 | S1PR2 (0.63) | S1PR2S1PR1ALDH1A1GPR84S1PR3 | |
| SCHEMBL4390623 | 0.91 | S1PR2 (0.63) | S1PR2S1PR1ALDH1A1GPR84S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| EP-2716642-B1 | IMIDAZOPYRIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
| US-6903233-B2 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1344763-A1 | Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters | Takasago International Corporation (JP) | 2003-09-17 | — | — | EP | disclosed |
| EP-0555537-B1 | Endothelin antagonists | BANYU PHARMA CO LTD (JP) | 2000-11-02 | — | — | EP | disclosed |
| US-5614498-A | OLIGOPEPTIDES, BRONCHDILATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5496928-A | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0555537-A2 | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | HDHD5, APEH, AOC3 | S1PR2 4547/4885S1PR1 4528/4885ALDH1A1 374/4885 |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | GUCY1A1, PDE2A, GUCY1A2 | S1PR2 1547/4885S1PR1 1340/4885ALDH1A1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.